Piper Sandler Maintains Overweight on Cara Therapeutics, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has maintained an Overweight rating on Cara Therapeutics (NASDAQ:CARA), but lowered the price target from $13 to $12.
August 08, 2023 | 7:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler has maintained an Overweight rating on Cara Therapeutics but lowered the price target from $13 to $12.
The news is directly about Cara Therapeutics. While the Overweight rating is positive, the lowering of the price target might have a neutral impact on the stock as it indicates a lower future valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100